MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgaf206

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2025

Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.

Ferrari Davide, Bonaventura Ilaria, Simeoli Chiara, Tomaselli Alessandra, Vincenzi Ludovica, De Alcubierre Dario, Sciarra Francesca, Rizzo Flavio, Cerroni Lorenzo, Di Paola Nicola, Minnetti Marianna, Sbardella Emilia, Venneri Mary Anna, Pofi Riccardo, Pivonello Rosario, Gianfrilli Daniele, Hasenmajer Valeria, Isidori Andrea M

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

CONTEXT: Medical therapy for Cushing syndrome (CS) typically aims to reduce daily cortisol output without addressing circadian rhythm restoration. No licensed drugs target this goal.

OBJECTIVE

We investigated the efficacy and safety of timed, once-daily osilodrostat administration in improving circadian cortisol profiles in CS.

METHODS

A prospective, multicenter study evaluated patients with well-controlled CS on a stable twice-daily osilodrostat therapy before and 60 to 90 days after transitioning to a single equivalent daily dose at 19:00 ± 1 hour. Circadian steroid analysis was performed on saliva, serum, and urine using ultra-high performance liquid chromatography-tandem mass spectrometry. Additional assessments included cardio-metabolic markers, quality of life, sleep function, and safety outcomes.

RESULTS

Sixteen patients (4 males; 7 pituitary, mean age 53.3 ± 11.8 years) were enrolled. At baseline, CS was well-controlled with a mean osilodrostat dose of 4.2 ± 1.3 mg. After transitioning, salivary cortisol exposure decreased significantly during the afternoon to early morning period (AUC16:00-08:00: -6.1 [-0.15 to -12.1] ng/mL/h, P = .029). Quality of life and sleep improved (CushingQoL: +4.2, P = .029; Pittsburgh Sleep Quality Index: -1.7, P = .049). Serum steroid precursors, including 11-deoxycorticosterone (-3.1 ng/mL/h, P = .008) and 11-deoxycortisol (-17.8 ng/mL/h, P = .005), decreased. Eight patients advancing dosing to 16:00 ± 1 hour showed comparable reductions, with phase shifts in acrophase and nadir. No patients developed adrenal insufficiency, liver toxicity, electrocardiogram abnormalities, or loss of disease control.

CONCLUSION

Once-daily osilodrostat effectively and safely treats patients with biochemically controlled CS, improving circadian cortisol profiles, quality of life, and sleep. Findings support further exploration of chronotherapy-based approaches in CS management.

Для цитирования: Ferrari Davide, Bonaventura Ilaria, Simeoli Chiara, Tomaselli Alessandra, Vincenzi Ludovica, De Alcubierre Dario, Sciarra Francesca, Rizzo Flavio, Cerroni Lorenzo, Di Paola Nicola, Minnetti Marianna, Sbardella Emilia, Venneri Mary Anna, Pofi Riccardo, Pivonello Rosario, Gianfrilli Daniele, Hasenmajer Valeria, Isidori Andrea M. Chronotherapy With Once-Daily Osilodrostat Improves Cortisol Rhythm, Quality of Life, and Sleep in Cushing's Syndrome.. The Journal of clinical endocrinology and metabolism. 2025. DOI: 10.1210/clinem/dgaf206.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.